Skip to content
Peptigraph home

VK2735: Trials and FDA Status

VK2735 is a glp-1/gip dual agonist. This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated

Where it stands

US status
Investigational
Phase
Phase 3
Sponsor
Viking Therapeutics
Expected FDA decision
None announced
no primary source states a date (checked 2 Oct 2026)
Trial IDs (NCT)
NCT06068946, NCT06828055, NCT07104500, NCT07104383
Results

Reported results

  • 2026VENTURE phase 2 (Obesity 2026): weight change at 13 weeks“Mean weight reduction with active treatment ranged from 9.2 kg (2.5 mg dose) to 14.6 kg (15 mg dose), corresponding to 9.1% and 14.7% weight reductions, respectively; the placebo group had a 1.8 kg (1.7%) reduction”pubmed.ncbi.nlm.nih.gov

Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.

Timeline

Milestones

  1. NCT07104500 (VANQUISH 1; Phase 3): primary completion (estimated)
  2. NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2); Phase 3): primary completion (estimated)
  3. Viking reports VANQUISH-1 and VANQUISH-2 phase 3 trials fully enrolled
  4. Published in Obesity (Silver Spring, Md.) (2026): Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.
  5. NCT07104500 (VANQUISH 1; Phase 3): first posted on ClinicalTrials.gov
  6. NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2); Phase 3): first posted on ClinicalTrials.gov
  7. NCT06828055 (VK2735 for Weight Management Phase 2 (Venture Oral Dosing); Phase 2): primary completion
  8. NCT07104500 (VANQUISH 1; Phase 3): study start
  9. NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2); Phase 3): study start
  10. NCT06828055 (VK2735 for Weight Management Phase 2 (Venture Oral Dosing); Phase 2): first posted on ClinicalTrials.gov
  11. NCT06828055 (VK2735 for Weight Management Phase 2 (Venture Oral Dosing); Phase 2): study start
  12. NCT06068946 (VENTURE; Phase 2): primary completion
  13. NCT06068946 (VENTURE; Phase 2): first posted on ClinicalTrials.gov
  14. NCT06068946 (VENTURE; Phase 2): study start

Sources

  1. 1VENTURE: VK2735 for Weight Management Phase 2 (NCT06068946)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
  2. 2VK2735 for Weight Management Phase 2 (Venture Oral Dosing) (NCT06828055)ClinicalTrials.gov (U.S. National Library of Medicine) · 2025clinicaltrials.govAccessed 2 Oct 2026
  3. 3VANQUISH 1: VK2735 for Weight Management Phase 3 (NCT07104500)ClinicalTrials.gov (U.S. National Library of Medicine) · 2025clinicaltrials.govAccessed 2 Oct 2026
  4. 4VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) (NCT07104383)ClinicalTrials.gov (U.S. National Library of Medicine) · 2025clinicaltrials.govAccessed 2 Oct 2026
  5. 5Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.Obesity (Silver Spring, Md.) · 2026PMID 41508550Accessed 2 Oct 2026
  6. 6Viking reports VANQUISH-1 and VANQUISH-2 phase 3 trials fully enrolledViking Therapeutics (press release) · 2026ir.vikingtherapeutics.comAccessed 2 Oct 2026

Found an error? Report a correction.